LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Geron Corp

Затворен

СекторЗдравеопазване

1.65 1.85

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.65

Максимум

1.6800000000000002

Ключови измерители

By Trading Economics

Приходи

-2.1M

-18M

Продажби

-1.8M

47M

EPS

-0.03

Марж на печалбата

-39.02

Служители

229

EBITDA

-2.1M

-9.7M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+145.4% upside

Дивиденти

By Dow Jones

Следващи печалби

25.02.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

262M

1B

Предишно отваряне

-0.2

Предишно затваряне

1.65

Настроения в новините

By Acuity

24%

76%

43 / 351 Класиране в Healthcare

Geron Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.02.2026 г., 16:32 ч. UTC

Печалби

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

14.02.2026 г., 22:02 ч. UTC

Печалби

Looking for Dividends? Consider Europe. -- Barrons.com

14.02.2026 г., 09:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

13.02.2026 г., 21:57 ч. UTC

Печалби

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

13.02.2026 г., 21:20 ч. UTC

Печалби

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13.02.2026 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13.02.2026 г., 20:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

13.02.2026 г., 20:45 ч. UTC

Пазарно говорене

Dollar Pares Down Early Losses -- Market Talk

13.02.2026 г., 20:39 ч. UTC

Пазарно говорене

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13.02.2026 г., 20:28 ч. UTC

Пазарно говорене

Oil Settles Week Lower -- Market Talk

13.02.2026 г., 19:51 ч. UTC

Печалби

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13.02.2026 г., 19:32 ч. UTC

Пазарно говорене

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13.02.2026 г., 19:32 ч. UTC

Пазарно говорене

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13.02.2026 г., 19:29 ч. UTC

Печалби

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13.02.2026 г., 18:18 ч. UTC

Придобивния, сливания и поглъщания

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13.02.2026 г., 17:52 ч. UTC

Печалби

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13.02.2026 г., 17:16 ч. UTC

Печалби

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13.02.2026 г., 17:10 ч. UTC

Придобивния, сливания и поглъщания

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13.02.2026 г., 16:59 ч. UTC

Печалби

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13.02.2026 г., 16:39 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13.02.2026 г., 16:11 ч. UTC

Печалби

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13.02.2026 г., 16:07 ч. UTC

Пазарно говорене

Hungarian Forint Could Rise Further -- Market Talk

13.02.2026 г., 15:54 ч. UTC

Печалби

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13.02.2026 г., 15:26 ч. UTC

Пазарно говорене

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13.02.2026 г., 15:01 ч. UTC

Печалби

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13.02.2026 г., 15:00 ч. UTC

Печалби

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13.02.2026 г., 14:50 ч. UTC

Пазарно говорене

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13.02.2026 г., 14:44 ч. UTC

Печалби

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13.02.2026 г., 14:22 ч. UTC

Пазарно говорене
Печалби

Global Energy Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Geron Corp Прогноза

Ценова цел

By TipRanks

145.4% нагоре

12-месечна прогноза

Среден 4 USD  145.4%

Висок 5 USD

Нисък 3 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Geron Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

3

Купи

1

Задържане

0

Продай

Настроение

By Acuity

43 / 351 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
help-icon Live chat